In humans, 18-OH-DOC is a weak mineralocorticoid.[3] It may be increased in 17α-hydroxylase (CYP17A1) deficiency,[4] in aldosterone synthase (CYP11B2) deficiency,[5] in primary aldosteronism, and may also indicate a histologic variant of the aldosteronoma.[4] Excessive secretion of 18-OH-DOC can cause mineralocorticoid excess syndrome, although these cases are very rare.[6]
References
^Fujii S, Momoi K, Okamoto M, Yamano T, Okada T, Terasawa T (June 1984). "18,19-Dihydroxydeoxycorticosterone, a new metabolite produced from 18-hydroxydeoxycorticosterone by cytochrome P-450(11) beta. Chemical synthesis and structural analysis by 1H NMR". Biochemistry. 23 (12): 2558–64. doi:10.1021/bi00307a004. PMID6466598.
^Zhou MY, Gomez-Sanchez EP, Foecking MF, Gomez-Sanchez CE (October 1995). "Cloning and expression of the rat adrenal cytochrome P-450 11B3 (CYP11B3) enzyme cDNA: preferential 18-hydroxylation over 11 beta-hydroxylation of DOC". Molecular and Cellular Endocrinology. 114 (1–2): 137–45. doi:10.1016/0303-7207(95)03653-o. PMID8674838. S2CID53252461.
^ abUlick S (November 1976). "Adrenocortical factors in hypertension. I. Significance of 18-hydroxy-11-deoxycorticosterone". The American Journal of Cardiology. 38 (6): 814–24. doi:10.1016/0002-9149(76)90360-x. PMID187051.
^Riepe FG, Krone N, Peter M, Sippell WG, Partsch CJ (March 2003). "Chromatographic system for the simultaneous measurement of plasma 18-hydroxy-11-deoxycorticosterone and 18-hydroxycorticosterone by radioimmunoassay: reference data for neonates and infants and its application in aldosterone-synthase deficiency". Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 785 (2): 293–301. doi:10.1016/s1570-0232(02)00921-2. PMID12554142.